Copyright ©The Author(s) 2021.
World J Gastrointest Oncol. Jun 15, 2021; 13(6): 574-588
Published online Jun 15, 2021. doi: 10.4251/wjgo.v13.i6.574
Table 1 The ongoing clinical trials of poly adenosine diphosphate-ribose polymerase-1 inhibitor for the treatment of colorectal cancer
Trial ID
Target Indication
Outcome measurement
OlaparibNCT04456699Unresectable or metastatic CRC patients who have not progressed following first-line therapy of FOLFOX with bevacizumabPrimary: PFS (up to 6 yr); Secondary: OS, ORR, DOR, AE (up to 6 yr)(1) Olaparib; (2) Olaparib + Bevacizumab; (3) 5-FU + Bevacizumab; Triple-arms
OlaparibNCT04166435O6-MGMT hypermethylated CRC patientsPrimary: ORR (up to 2 yr); Secondary: AE, PFS, OS (up to 2 yr)Temozolomide + Olaparib; Single-arm
NiraparibNCT03983993Patients with metastatic CRCPrimary: Clinical benefit rate (CR + PR + SD, up to 5 yr); Secondary: ORR, DOR, PFS, OS (up to 5 yr)Niraparib + Panitumumab; Single-arm
RucaparibNCT03337087Treating patients with metastatic CRC up to third-line of prior therapyPrimary: MTD, DLT, ORR (SD, CR, PR; up to 3 yr); Secondary: DCR, PFS, OS, AE (up to 3 yr)liposomal irinotecan + 5-FU + rucaparib; Single-arm